Tests sirolimus in people with dilated heart disease and Kaposi sarcoma virus
Tests sirolimus added to standard care in adults with dilated cardiomyopathy and KSHV infection.
Plain-language title generated from the registry record
Registry title: The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with dilated cardiomyopathy (a weakened, enlarged heart) who carry Kaposi sarcoma-associated virus (KSHV). It tests sirolimus added to standard treatment.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Dilated cardiomyopathy shown on heart imaging: left ventricular ejection fraction <45% and/or fractional shortening <25%, and left ventricular end-diastolic diameter >117% of the predicted value. No severe coronary artery disease or valvular disease.
- Earlier treatment
- Patients must have been optimally managed. Participation in any drug trial within the last 3 months is not allowed.
- Biomarker or test result
- KSHV DNA seropositivity (a positive test for the virus).
Main reasons for not taking part
- Allergy to rapamycin or its derivatives
- Low neutrophils (less than 0.5*10^9/L) or low platelets (less than 2.5*10^10/L)
- Pregnant, or planning to become pregnant
- Serious neurological disease, such as Alzheimer's disease or Parkinson syndrome
- Past cancer or tumor, or confirmed precancerous lesions
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06236022, who can take part
Where in China
- Tongji HospitalWuhan, ChinaContact: Yanru Zhao, DoctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tongji Hospital
- Trial code
- NCT06236022
- Record updated
- 1 February 2024
- Original description
Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.Read full original descriptionShow less
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.
Inclusion: 18 to 70 years of age; Diagnosed as dilated cardiomyopathy. Specifically, (i) left ventricular ejection fraction <45% (>2 SD) and/or fractional shortening <25% (>2 SD), as ascertained by echocardiography, radionuclide scanning, or cardiac magnetic resonance imaging; (ii) left ventricular end-diastolic diameter >117% of the predicted value corrected for age and body surface area (Henry's formula), which corresponds to 2 SD of the predicted normal limit +5%; and (iii) In the absence of severe coronary artery disease or valvular disease; KSHV DNA seropositivity; Patients are voluntary and signed informed consent.
Exclusion: Participate in any drug clinical trials within 3 months; Allergic to rapamycin or its derivatives；; Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients); Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions; The proportion of neutrophils less than 0.5*10\^9/L or platelet less than 2.5*10\^10/L; Pregnant women or plan to; Patients were not optimally managed.